CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12:286–295.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43:682–689.
   PubMed Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–754.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–1809.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Delasalle K, Wang M, et al. Curability of multiple myeloma. Bone Marrow Res. 2012;2012:916479.
   PubMedGoogle Scholar
• Barlogie B, Mitchell A, van Rhee F, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–3051.
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–290.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Callahan MK, Postow MA, et al. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015;7:280sr281.
   Web of Science ®Google Scholar
• Themeli M, Riviere I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015;16:357–366.
   PubMed Web of Science ®Google Scholar
• Festuccia M, Martino M, Ferrando F, et al. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opin Biol Ther. 2015;15:857–872.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267–1273.
   PubMed Web of Science ®Google Scholar
• Smith E, Devlin SM, Kosuri S, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2016;22:258–267.
   PubMedGoogle Scholar
• Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–1198.
   PubMed Web of Science ®Google Scholar
• Noonan K, Borrello I. The immune microenvironment of myeloma. Cancer Microenviron. 2011;4:313–323.
   PubMedGoogle Scholar
• Gorgun GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121:2975–2987.
   PubMed Web of Science ®Google Scholar
• An G, Acharya C, Feng X, et al. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016;128:1590–1603.
   PubMed Web of Science ®Google Scholar
• Goodyear O, Piper K, Khan N, et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood. 2005;106:4217–4224.
   PubMed Web of Science ®Google Scholar
• Brown RD, Spencer A, Ho PJ, et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk Lymphoma. 2009;50:1860–1864.
   PubMed Web of Science ®Google Scholar
• Tyler EM, Jungbluth AA, O'Reilly RJ, et al. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood. 2013;121:308–317.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Bertz H, Spyridonidis A, et al. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant. 2004;34:923–928.
   PubMed Web of Science ®Google Scholar
• Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000;6:375–386.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548–1556.
   PubMed Web of Science ®Google Scholar
• Montefusco V, Spina F, Patriarca F, et al. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:424–428.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Crocchiolo R, Furst S, et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol. 2012;40:521–527.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–5239.
   PubMed Web of Science ®Google Scholar
• Borrello I, Noonan KA. Marrow-infiltrating lymphocytes – role in biology and cancer therapy. Front Immunol. 2016;7:112.
   PubMed Web of Science ®Google Scholar
• Noonan KA, Huff CA, Davis J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015;7:288ra278.
   Web of Science ®Google Scholar
• Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5:197ra103.
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863–871.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1–30.
   PubMed Web of Science ®Google Scholar
• Condomines M, Hose D, Raynaud P, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol. 2007;178:3307–3315.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21:914–921.
   PubMed Web of Science ®Google Scholar
• Sadelain M. T-cell engineering for cancer immunotherapy. Cancer J. 2009;15:451–455.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–398.
   PubMed Web of Science ®Google Scholar
• Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125:3392–3400.
   PubMed Web of Science ®Google Scholar
• Geyer MB, Brentjens RJ. Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016;18:1393–1409.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–528.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–2138.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra225.
   Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra138.
   Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040–1047.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Stadtmauer EA, Maus MV, et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. Am Soc Hematol. 2016;128:974.
   Google Scholar
• Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest. 2016;126:2588–2596.
   PubMed Web of Science ®Google Scholar
• Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94:318–323.
   PubMed Web of Science ®Google Scholar
• Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother. 2016;2:28–35.
   Google Scholar
• Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget. 2015;6:28693–28715.
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–2060.
   PubMed Web of Science ®Google Scholar
• Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187–1199.
   PubMed Web of Science ®Google Scholar
• Lee L, Bounds D, Paterson J, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174:911–922.
   PubMed Web of Science ®Google Scholar
• Dou H, Yan Z, Zhang M, et al. APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer. Oncol Lett. 2016;12:3351–3355.
   PubMed Web of Science ®Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–1700.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Am Soc Hematol. 2016;128:1147.
   Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao W, Liu J, et al. Phase I, open-label trial of anti-BCMA chimeric antigen receptor T cells in patients with relapsed/refractory multiple myeloma. 2017. Ferrata Storti Foundation Via Giuseppe Belli 4, Pavia, Italy. p. 2–3.
   Google Scholar
• Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 1996;10:1408–1417.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Steinbach M, Radhakrishnan SV, et al. Immunotherapies targeting CD38 in multiple myeloma. Oncoimmunology. 2016;5:e1217374
   PubMed Web of Science ®Google Scholar
• Touzeau C, Moreau P. Daratumumab for the treatment of multiple myeloma. Expert Opin Biol Ther. 2017;17:887–893.
   PubMed Web of Science ®Google Scholar
• Mihara K, Bhattacharyya J, Kitanaka A, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia. 2012;26:365–367.
   PubMed Web of Science ®Google Scholar
• Drent E, Groen RW, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101:616–625.
   PubMed Web of Science ®Google Scholar
• Tembhare P, Yuan C, Korde N, et al. Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leuk Lymphoma. 2012;53:721–724.
   PubMed Web of Science ®Google Scholar
• Munoz P, Navarro MD, Pavon EJ, et al. CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-zeta subunit of the T cell antigen receptor. J Biol Chem. 2003;278:50791–50802.
   PubMed Web of Science ®Google Scholar
• Kramer G, Steiner G, Fodinger D, et al. High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol. 1995;154:1636–1641.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122:3461–3472.
   PubMed Web of Science ®Google Scholar
• Shaffer DR, Savoldo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011;117:4304–4314.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:917–927.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Holland AM, van den Brink MR. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Immunol Rev. 2014;257:226–236.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Koestner W, Hapke M, et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. Blood. 2009;113:4440–4448.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Holland AM, Dogan Y, et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res. 2013;73:4687–4696.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Dogan Y, Moroz M, et al. Adoptively transferred TRAIL + T cells suppress GVHD and augment antitumor activity. J Clin Invest. 2013;123:2654–2662.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Smith M, James SE, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017;23:242–249.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–1121.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129–4139.
   PubMed Web of Science ®Google Scholar
• Holland AM, Zakrzewski JL, Goldberg GL, et al. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man. Semin Immunopathol. 2008;30:479–487.
   PubMed Web of Science ®Google Scholar
• Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008;26:453–461.
   PubMed Web of Science ®Google Scholar
• Hubner J, Hoseini SS, Suerth JD, et al. Generation of genetically engineered precursor T-cells from human umbilical cord blood using an optimized alpharetroviral vector platform. Mol Ther. 2016;24:1216–1226.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Purdon TJ, van Leeuwen DG, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415–422.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4:61–71.
   PubMed Web of Science ®Google Scholar
• Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296–304.
   PubMed Web of Science ®Google Scholar
• Yousef S, Marvin J, Steinbach M, et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J. 2015;5:e285.
   PubMed Web of Science ®Google Scholar
• Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013;27:464–472.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698–2704.
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14:3044–3051.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Mateos M-V, Shah JJ, et al. Pembrolizumab in Combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): keynote-023. Blood. 2015;126:505.
   Google Scholar
• Lonial S, Ribeiro de Oliveira M, Yimer H, et al. 51TiPKEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM). Ann Oncol. 2016;27:15.
   Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636–5646.
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255–2266.
   PubMed Web of Science ®Google Scholar
• Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol. 2001;125:190–197.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Nakamura K, Vuckovic S, et al. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 2016;73:1569–1589.
   PubMed Web of Science ®Google Scholar
• Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44:412–418.
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:394.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hughes MS, Zheng Z, et al. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol. 2005;175:7226–7234.
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71:3516–3527.
   PubMed Web of Science ®Google Scholar
• Hsu C, Jones SA, Cohen CJ, et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood. 2007;109:5168–5177.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130–3144.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Condomines M, van der Stegen SJ, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28:415–428.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–590.
   PubMed Web of Science ®Google Scholar
• Curran KJ, Seinstra BA, Nikhamin Y, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23:769–778.
   PubMed Web of Science ®Google Scholar